GALE 302

Drug Profile

GALE 302

Alternative Names: Attenuated E39 peptide vaccine - Galena Biopharma; E39 prime vaccine - Galena Biopharma; E39'; E39'-GM-CSF-vaccine - Galena Biopharma; EIWTFSTKV; FBP-J65; Folate binding protein J65 - Galena Biopharma; GALE-302; J65

Latest Information Update: 15 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Galena Biopharma
  • Class Antineoplastics; Cancer vaccines; Peptide vaccines; Peptides; Stem cell therapies
  • Mechanism of Action Folate receptor 1 modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Breast cancer; Ovarian cancer

Most Recent Events

  • 03 May 2017 GALE 302 is still at phase I/II development stage for Breast cancer and Ovarian cancer (Combination therapy, Adjuvant therapy, Prevention of relapse) in USA (Intradermal) (Galena Biopharma pipeline, May 2017)
  • 09 Mar 2017 COL George Peoples and M.D. Anderson Cancer Center completes a phase Ib/II trial in Breast cancer and Ovarian cancer (Prevention of relapse, Adjuvant therapy, Combination therapy) in USA before March 2017 (NCT02019524)
  • 14 Nov 2016 Analysis of post-booster immunogenicity data from a phase Ib trial in Ovarian cancer and Breast cancer released by Galena Biopharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top